The objective of this guideline is to provide up-to-date, evidence-based recommendations
for the management of SLE that builds upon the existing treatment guideline for adults living …

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disorder with
severe morbidity and mortality and diverse systemic involvement. Disease onset occurs …

Progress in medicine is mostly based on evidence from international collaborations and
trials, which are especially needed in infrequent diseases, such as SLE. In addition to …

Systemic lupus erythematosus (SLE) begins in childhood or adolescence in approximately
15% of cases, and although short-and long-term outcomes have improved considerably in …

Systemic lupus erythematosus (SLE) is the paradigm of systemic autoimmune diseases
characterised by a wide spectrum of clinical manifestations with an unpredictable relapsing …

Childhood-onset systemic lupus erythematosus (cSLE) is a rare, multisystem and potentially
life-threatening autoimmune disorder with significant associated morbidity. Evidence-based …

Caroline Gordon1, 2, 3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1, 3, Sue Brown4,
Ian N. Bruce5, 6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10, 11 …

Childhood-onset systemic lupus erythematosus (cSLE) is rare in many regions of the world,
including Europe. Access to approved medications for cSLE is currently limited, among …

Current studies highlighted the various facets of cSLE, epidemiology, clinical, laboratory,
classification criteria, adolescent issues, prognosis, surveillance, T2T approach and drug …

Lupus nephritis (LN) occurs in 50%–60% of patients with childhood-onset systemic lupus
erythematosus (cSLE), leading to significant morbidity. Timely recognition of renal …